Earnings calls

Astrazeneca Phar concall ledger

Every earnings call for ASTRAZEN — management tone, guidance, KPIs and promise tracking, quarter by quarter.

ASTRAZEN · 5 transcripts · Healthcare · latest Q1 FY26

Q1 FY26Published 14 Aug 2025Call held 14 Aug 2025

ASTRAZEN Q1 FY26 Earnings Call Transcript & Analysis

Revenue₹1,716 cr+32% YoYEPS₹46.3−27% YoY

Revenue ₹1,716 cr (+32% YoY); EPS ₹46.3 (−27% YoY). Revenue from operations for FY24-25 reached ₹1,716 crore, representing a 32% YoY growth.

Read full transcript & analysis

Q1 FY25Published 08 Aug 2024Call held 08 Aug 2024

ASTRAZEN Q1 FY25 Earnings Call Transcript & Analysis

Revenue₹1,330 cr+29% YoYEPS₹64.6+63% YoY

Revenue (FY24) ₹1,330 cr (+29% YoY); EPS ₹64.6 (+63% YoY). Total Revenue for FY23-24 reached ₹1,330 crores, representing a 29% YoY growth.

Read full transcript & analysis

Q1 FY24Published 14 Aug 2023Call held 14 Aug 2023

ASTRAZEN Q1 FY24 Earnings Call Transcript & Analysis

Product Sales₹947 cr+24% YoYTotal Comprehensive Income₹96.7 cr+62% YoYProfit Before Tax₹134 crEarnings Per Share₹39.7Employee Cost to Sales27.51%−9% YoY

Product Sales ₹947 cr (+24% YoY); Total Comprehensive Income ₹97 cr (+62% YoY); Profit Before Tax ₹134 cr. Product sales reached ₹947 crores (Rs. 9,470 million), representing a 24% YoY growth.

Read full transcript & analysis

Q1 FY23Published 08 Aug 2022Call held 08 Aug 2022

ASTRAZEN Q1 FY23 Earnings Call Transcript & Analysis

Revenue₹761.4 cr−2% YoY

Revenue ₹761 cr (−2% YoY). Revenue from sales stood at ₹761.4 crores, a slight decline of 2% YoY due to generic competition in key brands.

Read full transcript & analysis

Q1 FY22Published 09 Aug 2021Call held 09 Aug 2021

ASTRAZEN Q1 FY22 Earnings Call Transcript & Analysis

Revenue₹776.8 cr−3% YoYEBITDA Margin17%EPS₹37.3

Revenue ₹777 cr (−3% YoY); EBITDA Margin 17%; EPS ₹37.3. Registered annual sales of ₹776.8 crores (Rs. 7,768 million) for FY21, a decline of 3.1% YoY.

Read full transcript & analysis